Amundi Pioneer Asset Management Inc. Acquires 1,988 Shares of Allergan plc (NYSE:AGN)

Amundi Pioneer Asset Management Inc. increased its position in shares of Allergan plc (NYSE:AGN) by 0.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 345,860 shares of the company’s stock after purchasing an additional 1,988 shares during the period. Amundi Pioneer Asset Management Inc. owned 0.11% of Allergan worth $50,637,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in AGN. Oregon Public Employees Retirement Fund raised its stake in Allergan by 7.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 155,340 shares of the company’s stock worth $20,763,000 after buying an additional 10,235 shares during the period. First Trust Advisors LP raised its stake in shares of Allergan by 5.3% in the fourth quarter. First Trust Advisors LP now owns 168,937 shares of the company’s stock worth $22,580,000 after purchasing an additional 8,440 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Allergan by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 86,710 shares of the company’s stock worth $11,588,000 after purchasing an additional 5,799 shares during the last quarter. Stephens Inc. AR raised its stake in shares of Allergan by 0.9% in the fourth quarter. Stephens Inc. AR now owns 23,134 shares of the company’s stock worth $3,092,000 after purchasing an additional 203 shares during the last quarter. Finally, Bruderman Asset Management LLC purchased a new stake in shares of Allergan in the fourth quarter worth approximately $49,000. Hedge funds and other institutional investors own 80.08% of the company’s stock.

Shares of NYSE AGN traded up $1.11 during mid-day trading on Friday, hitting $163.16. 2,480,879 shares of the company’s stock traded hands, compared to its average volume of 6,768,697. The business has a 50-day moving average of $145.42. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.60. The company has a market capitalization of $53.12 billion, a P/E ratio of 9.78, a P/E/G ratio of 1.52 and a beta of 1.63. Allergan plc has a 1 year low of $114.27 and a 1 year high of $197.00.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.55 by $0.24. The firm had revenue of $3.60 billion for the quarter, compared to analysts’ expectations of $3.55 billion. Allergan had a negative net margin of 45.94% and a positive return on equity of 8.45%. The business’s revenue was down 2.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.74 EPS. On average, equities analysts expect that Allergan plc will post 16.72 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be given a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a yield of 1.81%. Allergan’s dividend payout ratio (DPR) is currently 17.74%.

Several analysts have recently commented on the company. Mizuho assumed coverage on Avrobio in a research note on Wednesday, June 26th. They issued a “buy” rating and a $28.00 price objective for the company. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 280 ($3.66) price objective on shares of in a research note on Wednesday, June 19th. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a research note on Tuesday, June 25th. Jefferies Financial Group assumed coverage on Pinduoduo in a research report on Monday, April 15th. They set a “buy” rating and a $30.00 price target for the company. Finally, Sanford C. Bernstein downgraded Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target for the company. in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $176.27.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Recommended Story: Fiduciary

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.